Physician Experiences With and Perspectives on Clozapine Prescribing.

ABSTRACT:

Importance

Clozapine is an effective medication for treatment-resistant schizophrenia but can cause agranulocytosis. Since its approval, patients taking clozapine have been required to undergo regular blood testing to screen for neutropenia. In 2015, the risk management programs were merged into a single risk evaluation and mitigation strategy (REMS), which mandates that prescribers undergo a certification process in which they attest to understanding the risk of agranulocytosis and commit to performing required blood testing. It is unknown how the clozapine REMS program has affected clinical practice.

Objective

To understand physicians' perceptions of and experiences with the clozapine REMS program.

Design, setting, and participants

This survey study included US phys

SUBMITTER: Sarpatwari A 

PROVIDER: S-EPMC11826364 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature